Toggle Nav
My Cart
Search
Menu
Account
Settings
Healthcare Price Point Analysis for Laboratory Developed Tests (LDTs) and FDA Regulated Tests

Discover the Perfect Assay Price Point to Remain Competitive

INDUSTRY
Healthcare

RELEASE DATE
12-Sep-2016
REGION
North America
DELIVERABLE TYPE
Market Research

RESEARCH CODE
9AB9-00-55-00-00
SKU
HC02677-NA-MR_18988
Yes
SHARE

Price Point Analysis for Laboratory Developed Tests (LDTs) and FDA Regulated Tests
Published on: 12-Sep-2016 | SKU: HC02677-NA-MR_18988

Need more details?

$1,500.00

$1,125.00 save 25 %

DownloadLink
Request Sample
Add to Compare
Need more details?
Description

The main objective of this research is to estimate test volumes and unit prices for a wide variety of LDTs (genetic) and a few high volume FDA tests for selective therapeutic areas. The tests are categorized by their intended uses across the diagnostic spectrum (risk assessment, screening, diagnosis, staging and prognosis, therapy selection, therapy monitoring). A selective list of therapeutic areas covered in this research include: autoimmune diseases, cancers (breast, colorectal, prostrate, lung, gastric, cervical, and ovarian), toxicology, cardiology, women’s health (vitamin D, prenatal, pregnancy and hormone), and infectious disease testing (TB, hepatitis A/B/C, cytomegalovirus). The base year used for analysis is 2015.

Table of Contents

Research Scope

Executive Summary

Executive Summary (continued)

Executive Summary (continued)

Research Objectives

Abbreviations

Celiac Disease Specific LDT Assays

Chron’s Disease Specific LDT Assays

Rheumatoid Arthritis Specific LDT Assays

Lupus Specific LDT Assays

LupusSpecific LDT Assays (continued)

IBD and IBS Specific LDT Assays

Biomarker Guidelines

Cardiac Disease Specific LDTs and FDA Assays

Cardiac Disease Specific LDTs and FDA Assays (continued)

Prostate Cancer Specific LDT Assays

Prostate Cancer Specific LDT Assays (continued)

Breast Cancer Specific LDT Assays

Breast Cancer Specific LDT Assays (continued)

Breast Cancer Specific LDT Assays (continued)

Colon Cancer Specific LDT and CLIA Waived Assays

Colon Cancer Specific LDT and CLIA Waived Assays (continued)

Colon Cancer Specific LDT and CLIA Waived Assays (continued)

Lung Cancer Specific LDT and FDA Assays

Lung Cancer Specific LDT and FDA Assays (continued)

Gynecologic Cancers (Ovarian)Specific LDT and FDA Assays

Gynecologic Cancers (Cervical)Specific LDT and FDA Assays

Biomarker Guidelines

Gastric Cancer/GIST Specific LDT and FDA Assays

Women’s Health Vitamin D Tests

Women’s Health Prenatal Tests

Women’s Health Pregnancy and Hormone Tests

Toxicology Popularly Ordered Tests

Infectious Diseases Popularly Ordered Genetic Tests

Infectious Diseases Popularly Ordered Tests

Legal Disclaimer

The Frost & Sullivan Story

Value Proposition—Future of Your Company & Career

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Our Blue Ocean Strategy

Request Sample

Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related In Vitro Diagnostics (IVD) research

27 Aug 2026   |   Global   |   Frost Radar

Frost Radar: AI-Powered Molecular Diagnostics, 2026

AI-powered molecular diagnostics is an emerging and moderately fragmented industry that includes molecular diagnostics companies, precision medicine platforms, sequencing specialists, AI-driven analytics providers, and disease-focused biotechnology companies. No single company has dominated, present...

25 Aug 2026   |   Global   |   Technology Research

Breakthrough Innovations in Point-of-Care Diagnostics

This research analyzes how point-of-care (PoC) diagnostics is evolving from simple tests to decentralized, connected, and clinically actionable testing platforms across hospitals, outpatient settings, homes, and pharmacies.The study assesses key technology shifts, including rapid molecular testing, ...

21 Aug 2026   |   Global   |   Technology Research

Innovations and Growth Opportunities in AI-Driven Biomanufacturing, Advanced Cell and Gene Therapies, and Precision Immunotherapy

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping biomanufacturing, cell and gene therapy, precision immunotherapy, anti-infectives, and neurotherapeutics across oncology, infectious disease...

07 Aug 2026   |   Global   |   Customer Research

Laboratory Product Purchasing Trends, United States and Europe, 2025–2026

Qualified respondents to this Frost & Sullivan survey were invited to participate in an online survey examining their laboratory’s product purchasing process in 2025 and expectations for 2026. Frost & Sullivan has conducted similar studies among the same target respondent groups since 2012. The surv...

21 Jul 2026   |   Global   |   Market Research

Point-of-Care Testing Market, Global, 2024–2031

The global POCT market is rapidly evolving from standalone rapid diagnostics to connected, AI-enabled clinical intelligence ecosystems that support decentralized healthcare delivery. Growth is driven by the increasing demand for faster clinical decision-making, early disease detection, personalized ...

 

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts
Related Research
  1. Innovations and Growth Opportunities in AI-Driven Drug Discovery, Precision Diagnostics, Advanced Biologics, and Next-generation Vaccines
    Release Date: 17-Jul-26
  2. Next-Generation Therapeutic Platforms: AI-Enabled Drug Discovery, Small molecules, Deep Proteomics, RNA Engineering, and Targeted Immunomodulation
    Release Date: 23-Jan-26
  3. Innovations and Growth Opportunities in AI-Driven Drug Discovery, Protein Engineering, Genomic Diagnostics, Advanced Drug Delivery, and Precision Medicine
    Release Date: 19-Jun-26
  4. Innovations and Growth Opportunities in Advanced Biologic Therapies, AI-powered Diagnostics, Drug Delivery Platforms, and Precision Medicine
    Release Date: 17-Apr-26
  5. Innovations and Growth Opportunities in Advanced RNA Therapies, Cancer Vaccines, Immunotherapies, and Precision Medicine
    Release Date: 22-May-26

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.

The main objective of this research is to estimate test volumes and unit prices for a wide variety of LDTs (genetic) and a few high volume FDA tests for selective therapeutic areas. The tests are categorized by their intended uses across the diagnostic spectrum (risk assessment, screening, diagnosis, staging and prognosis, therapy selection, therapy monitoring). A selective list of therapeutic areas covered in this research include: autoimmune diseases, cancers (breast, colorectal, prostrate, lung, gastric, cervical, and ovarian), toxicology, cardiology, women’s health (vitamin D, prenatal, pregnancy and hormone), and infectious disease testing (TB, hepatitis A/B/C, cytomegalovirus). The base year used for analysis is 2015.
More Information
Deliverable Type Market Research
No Index No
Podcast No
Author Divyaa Ravishankar
Industries Healthcare
WIP Number 9AB9-00-55-00-00
Is Prebook No

Price Point Analysis for Laboratory Developed Tests (LDTs) and FDA Regulated Tests

$1,500.00

Special Price $1,125.00 save 25 %

In stock
SKU
HC02677-NA-MR_18988